Outcome with Hyper-CVAD/MTX-Ara-C, a dose-intensive regimen, in acute lymphocytic leukemia and highly aggressive lymphoma: A preliminary study in a single center in China.

被引：0
|
作者：
Niu, Ting [1 ]
Liu, Ting [1 ]
Xiang, Bing [1 ]
Chang, Hong [1 ]
Jia, Yong-qian [1 ]
Zhu, Huan-ling [1 ]
机构：
[1] Sichuan Univ, W China Hosp, Dept Hematol, Chengdu 610064, Peoples R China
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4529
引用
收藏
页码：211B / 212B
页数：2
相关论文
共 11 条
  • [1] Outcome with Hyper-CVAD/MTX-Ara-C, a dose-intensive regimen, in acute lymphocytic leukemia and highly aggressive lymphoma in China.
    Niu, Ting
    Liu, Ting
    Xiang, Bing
    Chang, Hong
    Jia, Yong-qian
    Zhu, Huan-ling
    BLOOD, 2007, 110 (11) : 150B - 150B
  • [2] RESULTS OF TREATMENT WITH HYPER-CVAD MTX-ARA-C, A DOSE-INTENSIVE REGIMEN, IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA AND HIGHLY AGGRESSIVE LYMPHOMA IN A SINGLE CENTER IN CHINA
    Niu, T.
    Liu, T.
    Xiang, B. X.
    Jia, Y-O.
    Zhu, H. -L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 4 - 4
  • [3] Update of the HYPER-CVAD dose-intensive regimen in adult acute lymphocytic leukemia (ALL).
    Kantarjian, H
    O'Brien, S
    Keating, MJ
    Cortes, J
    Giles, FJ
    Beran, M
    Koller, C
    Andreeff, M
    Kornblau, S
    Pierce, S
    Murphy, S
    Freireich, EJ
    BLOOD, 1998, 92 (10) : 313A - 313A
  • [4] Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
    Kantarjian, HM
    O'Brien, S
    Smith, TL
    Cortes, J
    Giles, FJ
    Beran, M
    Pierce, S
    Huh, Y
    Andreeff, M
    Koller, C
    Ha, CS
    Keating, MJ
    Murphy, S
    Freireich, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 547 - 561
  • [5] Hyper-CVAD and high dose methotrexate/ARA-C (HD MTX-ARA-C) followed by stem cell transplantation for aggressive mantle cell lymphoma (MCL).
    Khouri, I
    Romaguera, J
    Kantarjian, H
    Pugh, W
    Przepiorka, D
    Rodriguez, A
    Samuels, BI
    vanBesien, K
    Giralt, S
    McLaughlin, P
    Claxton, D
    Mirza, NO
    Gajewski, J
    Mehra, R
    Hagemeister, F
    Cabanillas, F
    Champlin, R
    BLOOD, 1996, 88 (10) : 475 - 475
  • [6] Long-term follow-up results of hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL).
    O'Brien, S
    Thomas, D
    Cortes, J
    Faderl, S
    Giles, F
    Pierce, S
    Shan, J
    Ferrajoli, A
    Keating, M
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 567S - 567S
  • [7] Treatment of adult acute lymphoblastic leukemia (ALL) with the hyper-CVAD regimen - Preliminary analysis from a single center
    Marinakis, T
    Zomas, A
    Michalis, E
    Gortzolidis, G
    Galanopoulos, A
    Grigoraki, V
    Paterakis, G
    Leivada, A
    Griva, E
    Papadimitriou, E
    Skandalis, A
    BLOOD, 2002, 100 (11) : 272B - 272B
  • [8] Mantle cell lymphoma (MCL): Improved outcome with hyper-CVAD/high dose methotrexate-cytarabine (MTX-Ara-C) followed by autologous or allogeneic stem cell transplantation (SCT).
    Khouri, I
    Romaguera, J
    Kantarjian, H
    Pugh, W
    Palmer, J
    Przepiorka, D
    Rodriguez, A
    Samuels, B
    Giralt, S
    Gajewski, J
    Mehra, R
    Hagemeister, F
    Cabanillas, F
    Champlin, R
    BLOOD, 1997, 90 (10) : 2642 - 2642
  • [9] Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    Kantarjian, H
    Thomas, D
    O'Brien, S
    Cortes, J
    Giles, F
    Jeha, S
    Bueso-Ramos, CE
    Pierce, S
    Shan, JQ
    Koller, C
    Beran, M
    Keating, M
    Freireich, EJ
    CANCER, 2004, 101 (12) : 2788 - 2801
  • [10] High-dose cytarabine-mitoxantrone versus hyper-CVAD in adult acute lymphoblastic leukemia and Burkitt's lymphoma: A single center experience of two induction regimens.
    Lamba, Gurpreet Singh
    Pawar, Rahul
    Marballi, Abhishek
    Lee, Sang-Joon
    Liu, Delong
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12